Akers Biosciences Company Profile (NASDAQ:AKER)

Analyst Ratings

Consensus Ratings for Akers Biosciences (NASDAQ:AKER) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Akers Biosciences (NASDAQ:AKER)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Akers Biosciences (NASDAQ:AKER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/16/2016        
11/13/2015Q315($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/18/2015Q215($0.41)$1.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.10)($0.26)$2.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2015($0.16)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.17)($0.23)$1.40 million$453.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.16)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akers Biosciences (NASDAQ:AKER)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Akers Biosciences (NASDAQ:AKER)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Akers Biosciences (NASDAQ:AKER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/24/2016John J GormallyCEOBuy2,500$2.23$5,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Raymond Francis Akers JrChairmanBuy2,100$1.34$2,814.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Gary M RauchVPBuy3,500$1.50$5,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2014Gary M RauchVPBuy1,020$3.15$3,213.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Akers Biosciences (NASDAQ:AKER)
DateHeadline
07/15/16 01:00 PMResearch focused on the point of care (POC) analyzers market pipeline assessment and trends 2016
07/12/16 02:28 PMExplore breath analyzers market analysis & global forecast to 2019
07/01/16 10:23 AMToday’s Biggest Advancers on Wall Street: CLCD, APWC, AKER, AVXL, DYNT, AVNW, SCHN
06/30/16 02:27 PMAkers Biosciences : Says Rapid Chlamydia Test Trial "Highly Successful"
06/30/16 02:27 PMAkers Biosciences (AKER) Completes PIFA/Chlamydia Rapid Assay Clinical Trial; Notes 'Highly Successful' Results
06/28/16 07:35 AMNot a Pretty Day for the Market
06/28/16 07:35 AMAkers Biosciences Inc. (AKER) Surged On Distribution Agreement
06/28/16 07:35 AMAkers Biosciences founder expects more deals this year
06/27/16 02:44 PMProactive news highlights: FairFX, Allergy Therapeutics, SalvaRx, Akers Biosciences, GW Pharma & more
06/27/16 02:44 PMAkers Biosciences Inc. (AKER) Is Up Sharply After Distribution Agreement
06/27/16 02:44 PMAkers Biosciences (AKER) Signs First OxiChek Distribution Contract
06/27/16 07:09 AMAkers Biosciences Signs Distribution Agreement for BreathScan OxiChek™
06/22/16 07:12 AMBreath Analyzer Market Size to Reach $11.3 Billion by 2024: Grand View Research, Inc.
06/22/16 07:12 AMBiggest Stock Movers at the Close: MYOS, ASEI, CDXC, AKER, PSDV, STKS, CNXR
06/18/16 02:21 PMGlobal breath analyzers industry forecast to 2021 examined in new market
05/31/16 02:26 PMMarket Movers - Top risers and fallers between 15:00 and 16:00 - Overall Market John Lewis of Hungerford 1.02 0.00% Driver Group 46.50 0.00% Akers Biosciences Inc 137.50 0.00% Tracsis 477.50 0.00% P2P Global Investments 860.25 0.00% Young & Co's Brewery 1233.00 0.00% KEFI Minerals 0.62 0.00% Flying Brands 5.25 0.00% ...
03/03/16 01:20 PMAkers Receives Order for Rapid Assays in China; Shares Rise -
03/02/16 06:00 AMAkers Biosciences Announces $2.5M Order to Supply PIFA Heparin/PF4 Products to China - [Marketwired] - Akers Biosciences, Inc. , , a developer of health information technologies, announces the receipt of an order valued at approximately US$2,500,000 from NovoTek Therapeutics Inc. to supply PIFA Heparin ...
02/29/16 06:00 AMAkers Biosciences Hires Leading Commercial Executives to Support Sales Growth - [Marketwired] - Akers Biosciences, Inc. , , a developer of health information technologies, has further strengthened its commercial team with the appointments of Doug Carrara and Tony Saporito in senior sales and marketing ...
02/25/16 07:00 AMOxySure (OXYS) Ramps Up Production as Growth Continues - [Accesswire] - REDONDO BEACH, CA / ACCESSWIRE / February 25, 2016 / OxySure Therapeutics Inc. (OTCQB: OXYS) has grown its revenue for an impressive 15 consecutive quarters. While several analysts have taken note, setting ...
02/08/16 11:19 AMAkers Biosciences to Present at Disruptive Growth & Healthcare Conference - [GlobeNewswire] - THOROFARE, N.J., Feb. 08, 2016-- Akers Biosciences, Inc.,, a developer of cutting edge technologies that deliver rapid health information, is presenting at Source Capital’ s 2016 Disruptive Growth& Healthcare ...
01/21/16 06:01 PMAkers Biosciences Inc. (AKER) - 3-Dec-15 AKERS BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principa 16-Nov-15 AKERS BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit ...
12/08/15 12:17 PMAKERS BIOSCIENCES INC Financials -
12/03/15 03:31 PMAKERS BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principa -
12/03/15 11:50 AMAkers Biosciences JV Facility Now Operational in China -
12/01/15 08:37 AMAkers Biosciences Updates on Joint Venture in China - [at noodls] - THOROFARE, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ('Akers Bio' or the 'Company'), a developer and supplier of screening and testing technologies designed ...
12/01/15 03:49 AMAkers Biosciences Appoints Medical Technology Specialist as CEO - [at noodls] - THOROFARE, N.J., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ('Akers Bio' or the 'Company'), a medical device company focused on reducing the cost of healthcare ...
12/01/15 03:49 AMAkers Biosciences to Present at 8th Annual LD Micro Investor Conference - [at noodls] - THOROFARE, N.J., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ('Akers Bio' or the 'Company'), a developer of cutting edge technologies that deliver rapid health ...
12/01/15 03:49 AMAkers Biosciences Announces Q3 2015 Earnings - [at noodls] - Flagship Rapid HIT Test Set to be in 250 US Hospitals by Year End Conference Call Scheduled for 9:00 a.m. EST Today THOROFARE, N.J., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) ...
12/01/15 03:49 AMAkers Biosciences Appoints Dr. Raza Bokhari as Non-executive Director - [at noodls] - THOROFARE, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), (the 'Company'), a medical device company focused on reducing the cost of healthcare through faster, ...
11/30/15 09:03 AMAkers Biosciences, Inc. Earnings Q3, 2015 -
11/16/15 09:14 AMAKERS BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit -
11/16/15 08:00 AMAkers Biosciences (AKER) Q3 Loss Widens Y/Y, Shares Tank -

Social

About Akers Biosciences

No company description available

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKER
  • CUSIP:
Key Metrics:
  • Previous Close: $2.88
  • 50 Day Moving Average: $2.44
  • 200 Day Moving Average: $1.83
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $15.68M
  • Beta: 0.51
  • Current Year EPS Consensus Estimate: $-1.24 EPS
  • Next Year EPS Consensus Estimate: $-0.30 EPS
Additional Links:
Akers Biosciences (NASDAQ:AKER) Chart for Monday, July, 25, 2016